AGIO241220P22500
- 1.60
- 0.000.00%
Agios Pharmaceuticals Newsroom
Scotiabank Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $75
RBC Raises Price Target on Agios Pharmaceuticals to $57 From $55, Keeps Outperform Rating
Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank
Agios Pharmaceuticals Analyst Ratings
Scotiabank Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $75
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Leerink Partners Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating
Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Scotiabank Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $53
RBC Capital Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $55
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Piper Sandler Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $56
Agios Pharmaceuticals Price Target Announced at $51.00/Share by Scotiabank
Leerink Partners Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating
Raymond James Upgrades Agios Pharmaceuticals(AGIO.US) to Buy Rating, Announces Target Price $51
Agios Pharmaceuticals Analyst Ratings
Agios Pharmaceuticals Initiated With an Outperform at Raymond James
Leerink Partners Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Maintains Target Price $56
Leerink Partners Downgrades Agios Pharmaceuticals(AGIO.US) to Hold Rating, Cuts Target Price to $56